Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.

Jeon JY, Im YJ, Kim Y, Han SM, Jo MJ, Shin DH, Yoo JS, Moon BK, Kim BK, Lee BH, Choi YH, Cho BS, Jang HY, Chae SW, Kim MG.

Drug Dev Ind Pharm. 2013 Sep;39(9):1296-9. doi: 10.3109/03639045.2012.725732. Epub 2012 Oct 3.

PMID:
23030309
2.

Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions.

Tjandrawinata RR, Setiawati E, Yunaidi DA, Simanjuntak R, Santoso ID, Susanto LW.

Drug Des Devel Ther. 2013 Aug 20;7:841-7. doi: 10.2147/DDDT.S47272. eCollection 2013.

3.

Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers.

Liu J, Wu L, Hu X, Wu G, Zheng Y, Zhou H, Zhai Y, Zhu M, ShenTu J.

Int J Clin Pharmacol Ther. 2015 Jul;53(7):573-81. doi: 10.5414/CP202208.

PMID:
25828636
4.

Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.

Hübner R, Högemann AM, Sunzel M, Riddell JG.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S19-25.

PMID:
9331000
5.
6.

Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.

Spínola AC, Almeida S, Filipe A, Neves R, Trabelsi F, Farré A.

Clin Ther. 2009 Sep;31(9):1992-2001. doi: 10.1016/j.clinthera.2009.09.002.

PMID:
19843489
7.

Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.

Iqbal M, Khuroo A, Batolar LS, Tandon M, Monif T, Sharma PL.

Clin Ther. 2010 Mar;32(3):588-96. doi: 10.1016/j.clinthera.2010.03.004.

PMID:
20399995
8.

Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.

Yi S, Kim TE, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.

J Cardiovasc Pharmacol. 2011 Jun;57(6):682-9. doi: 10.1097/FJC.0b013e31821795d0.

PMID:
21394036
9.

Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.

Malerczyk C, Fuchs B, Belz GG, Roll S, Butzer R, Breithaupt-Grögler K, Herrmann V, Magin SG, Högemann A, Voith B, Mutschler E.

Br J Clin Pharmacol. 1998 Jun;45(6):567-73.

10.

Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers.

Nam JH, Oh M, Kim HJ, Han SK, Kim EJ, Song GS, Kim EY, Shin JG, Ghim JL, Kim HS.

Int J Clin Pharmacol Ther. 2015 Jan;53(1):66-74. doi: 10.5414/CP202045.

PMID:
25034618
11.

Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers.

Wittayalertpanya S, Chariyavilaskul P, Prompila N, Sayankuldilok N, Eiamart W.

Int J Clin Pharmacol Ther. 2014 May;52(5):431-6. doi: 10.5414/CP202051.

PMID:
24725445
12.
13.
14.

Clinical pharmacokinetics of candesartan.

Gleiter CH, Mörike KE.

Clin Pharmacokinet. 2002;41(1):7-17. Review.

PMID:
11825094
15.

Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function.

Hoogkamer JF, Kleinbloesem CH, Ouwerkerk M, Högemann A, Nokhodian A, Kirch W, Weidekamm E.

Eur J Clin Pharmacol. 1998 Jun;54(4):341-5.

PMID:
9696961
16.

Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers.

Liu YM, Zhang KE, Liu Y, Zhang HC, Song YX, Pu HH, Lu C, Liu GY, Jia JY, Zheng QS, Zhu JM, Yu C.

Clin Ther. 2012 Nov;34(11):2212-20. doi: 10.1016/j.clinthera.2012.10.001. Epub 2012 Oct 17.

PMID:
23084093
17.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.

Chi YH, Lee H, Paik SH, Lee JH, Yoo BW, Kim JH, Tan HK, Kim SL.

Am J Cardiovasc Drugs. 2011 Oct 1;11(5):335-46. doi: 10.2165/11593840-000000000-00000.

PMID:
21910510
19.

Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.

Lee D, Lim LA, Jang SB, Lee YJ, Chung JY, Choi JR, Kim K, Park JW, Yoon H, Lee J, Park MS, Park K.

Clin Ther. 2011 Dec;33(12):2038-53. doi: 10.1016/j.clinthera.2011.10.024. Epub 2011 Nov 29.

PMID:
22129569

Supplemental Content

Support Center